Glypican 3 Protein, Human, Recombinant (His Tag)


Glypican 3 Protein, Human, Recombinant (His Tag): Product Information

> 87 % as determined by SDS-PAGE
< 1.0 EU per μg of the protein as determined by the LAL method
Measured by its binding ability in a functional ELISA . Immobilized human GPC3 at 5 μg/ml (100 μl/well) can bind human bFGF / FGF2 with a linear range of 0.156-2.5 ng/ml.
Protein Construction
A DNA sequence encoding the human GPC3 (P51654-1) (Met1-His559) was expressed with a C-terminal polyhistidine tag.
Expressed Host
HEK293 Cells
Predicted N Terminal
Gln 25 & Ser 359
Molecule Mass
The recombinant human GPC3 comprises 546 amino acids and has a predicted molecular mass of 62 kDa, Cleaved partially by a furin-like convertase to N and C-terminal fragment with predicted molecular mass of 38 KDa and 24 kDa.
Lyophilized from sterile PBS, pH 7.4
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

Glypican 3 Protein, Human, Recombinant (His Tag): Images

Measured by its binding ability in a functional ELISA. Immobilized human GPC3 at 5 μg/ml (100 μl/well) can bind human bFGF / FGF2 with a linear ranger of 0.156-2.5 ng/ml.

Glypican 3 Protein, Human, Recombinant (His Tag): Synonyms

DGSX Protein, Human; Glypican 3 Protein, Human; GTR2-2 Protein, Human; MXR7 Protein, Human; OCI-5 Protein, Human; SDYS Protein, Human; SGB Protein, Human; SGBS Protein, Human; SGBS1 Protein, Human

Glypican 3 Background Information

Glypican-3, also known as Intestinal protein OCI-5, GPC3, and OCI5, is a member of the glypican family. It belongs to the glypican family and is highly expressed in the lung, liver, and kidney. It is a heparan sulfate proteoglycan, which is overexpressed in various neoplasms such as hepatocellular carcinoma, malignant melanoma, and testicular yolk sac tumor, and plays an important role in cell growth and differentiation. GPC3 function is tissue-dependent. In some tissues, GPC3 acts as a tumor suppressor gene, whereas in others, it acts as an oncofetal protein. Studies have shown that GPC3 is a reliable marker for hepatocellular carcinoma. The sensitivity and specificity exceed both alpha-fetoprotein and hepatocyte-paraffin1. GPC3 immunohistochemistry can aid in the differentiation of testicular germ cell tumors, being expressed in all yolk sac tumors but not in seminomas. GPC3 expression has also been identified in some squamous cell carcinomas of the lung and clear cell carcinomas of the ovary. The role of GPC3 in melanomas is still controversial. Thus, Glypican-3 is currently regarded as a tumor marker and potential target for immunotherapy.
Full Name
glypican 3
Research Areas
  • Kandil DH, et al. (2009) Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol. 16(2): 125-9.
  • Maeda D, et al. (2009) Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol. 22(6): 824-32.
  • A fluorescence based immunoassay for galectin-4 using gold nanoclusters and a composite consisting of glucose oxidase and a metal-organic framework
    Zhang, X;Zeng, Y;Zheng, A;Cai, Z;Huang, A;Zeng, J;Liu, X;Liu, J;
    Microchimica Acta
    assay validation
  • Elevated GPC3 level promotes cell proliferation in liver cancer
    Wang, S;Chen, N;Chen, Y;Sun, L;Li, L;Liu, H;
    Oncol Lett
  • Immunization with glypican-3 nanovaccine containing TLR7 agonist prevents the development of carcinogen-induced precancerous hepatic lesions to cancer in a murine model
    Chen, K;Wu, Z;Zang, M;Wang, C;Wang, Y;Wang, D;Ma, Y;Qu, C;
    Am J Transl Res
    cell-based (BMDC induction)
  • CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma
    Liu, G;Rui, W;Zheng, H;Huang, D;Yu, F;Zhang, Y;Dong, J;Zhao, X;Lin, X;
    Eur. J. Immunol.
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait U.S.A.